Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue (2016 - 2019)

Enanta Pharmaceuticals (ENTA) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $900000.0 as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Non-Current Deffered Revenue rose 51.77% year-over-year to $900000.0, compared with a TTM value of $900000.0 through Sep 2019, up 51.77%, and an annual FY2019 reading of $900000.0, up 51.77% over the prior year.
  • Non-Current Deffered Revenue was $900000.0 for Q3 2019 at Enanta Pharmaceuticals, down from $923000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $923000.0 in Q2 2019 and bottomed at $161000.0 in Q1 2015.
  • Average Non-Current Deffered Revenue over 5 years is $650789.5, with a median of $674000.0 recorded in 2018.
  • The sharpest move saw Non-Current Deffered Revenue surged 322.22% in 2015, then decreased 14.06% in 2018.
  • Year by year, Non-Current Deffered Revenue stood at $646000.0 in 2015, then increased by 8.51% to $701000.0 in 2016, then fell by 6.7% to $654000.0 in 2017, then increased by 3.06% to $674000.0 in 2018, then surged by 33.53% to $900000.0 in 2019.
  • Business Quant data shows Non-Current Deffered Revenue for ENTA at $900000.0 in Q3 2019, $923000.0 in Q2 2019, and $842000.0 in Q1 2019.